AI heavyweight Anthropic and its chief executive Dario Amodei have long asserted that their models could transform biology and drug discovery. In the company’s IPO filing on Monday, however, the tone was more modest, acknowledging a lack of hands‑on experience with physical experiments and the many hurdles that drug development entails. The path forward, it seems, will take time.
Two years ago, Amodei wrote that he was “open” to the notion that AI could deliver a millennium of biological progress within five to ten years. In August, he posted on X that “Anthropic is ramping up its efforts very quickly in biology and medicine.” In the same message he forecast that AI would enable cures for most human diseases within the next five to ten years and promised a “deluge of AI‑accelerated drugs.” The firm also highlighted the discovery of a “Crispr‑like” enzyme by its Claude model in September.
The new IPO filing still emphasizes AI’s capacity to “profoundly accelerate the rate of progress in biology and medicine” and to compress “decades of scientific progress into years,” but it is more cautious about how that promise will be realized. Anthropic notes that its teams “need first‑hand experience doing scientific research and drug discovery” and that its life‑sciences work will require “activities outside our historical experience as a software and research organization.” That includes handling hazardous substances, operating lab equipment and meeting a host of regulatory requirements.
The company also softened its language about the enzyme discovery, stating that it “might have the potential to be developed into a novel biotechnology tool, perhaps for gene editing.” Researchers previously told WIRED that they were skeptical of the enzyme’s value, and one scientist who studies the same enzymes raised concerns that Claude may have drawn on his work. Anthropic responded that neither its model nor its molecular biology team had access to the researcher’s material.
The filing indicates that Anthropic no longer sees itself merely as an external provider of AI tools to biotech firms; it now regards biotech discovery as a central component of its business. Like all biotech ventures, it faces the lengthy timeline of drug development. Even with AI assistance, any candidate must be validated in test tubes, then in animal models, and finally in human trials. While AI may help prioritize promising compounds, proving safety and efficacy still requires years of testing.
Anthropic acknowledges these obstacles in its filing: “Any drug candidates or other discoveries resulting from these efforts would face the lengthy, costly, and uncertain development and regulatory pathways characteristic of the life sciences industry, and may never generate revenue.” Amodei has previously argued for streamlined regulations to accommodate the upcoming wave of AI‑generated drugs.
SEC filings tend to be more guarded than public statements because of legal exposure to overstated claims. The IPO document makes clear that Anthropic believes its technology can drive transformative advances. Yet as the company pushes deeper into biological discovery, it will confront the same challenge as other biotech firms: demonstrating value through trials that cannot be rushed simply by adding more computing power.